HA HALO Halozyme Загрузка... : Бычьи и медвежьи мнения аналитиков

CMO/CDMO and SC formulation biotech companies like Halozyme and Alteogen offer high earnings visibility due to royalty-based models, making them attractive in a high-rate environment.

Buy HALO following good Q2 earnings; speaker finds valuation still attractive after results, suggesting the stock has not fully priced in the positive earnings outcome.

Author discloses Halozyme as one of their top 5 current holdings, indicating an active long position with personal conviction.

Author states a long position in HALO with no explicit catalyst; reply context references biotech sector strength relative to correcting AI/tech names, but no specific reasoning is provided by the author.

Speaker flags HALO as more interesting in the context of NVO's oral GLP-1 launch, with no explicit reason or price target provided.

Buy HALO as a top pick within specialty pharma; author nominates it as the most attractive name in the sector in response to a direct solicitation for ideas, though no specific catalyst or data point is provided.

The HALO ETF invests in companies with heavy physical assets and low obsolescence risk, making them immune to AI disruption. These are durable businesses that can withstand advances in large language models and agentic AI because their value is in hard assets, not software or services that could be displaced. The ETF provides a way to own the market while avoiding the most disruptive, AI-vulnerable names.

Long $HALO (Halozyme) — speaker massively reinforced position; sees HALO and GMAB as two siphons capturing Darzalex revenues.

Speaker positively characterizes the HALO trade as well considered and notes asset-light/durability as alpha hunting grounds, but does not commit to a personal directional position.